100 related articles for article (PubMed ID: 31237806)
1. Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.
Kelly RJ; Turner R; Chen YW; Rigas JR; Fernandes AW; Karve S
J Oncol Pract; 2019 Aug; 15(8):e717-e727. PubMed ID: 31237806
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
3. Metastatic non-small cell lung cancer: costs associated with disease progression.
Fox KM; Brooks JM; Kim J
Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
6. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
[TBL] [Abstract][Full Text] [Related]
7. Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer.
Geller AD; Zheng H; Mathisen DJ; Wright CD; Lanuti M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1804-1811. PubMed ID: 29254638
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
10. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
[TBL] [Abstract][Full Text] [Related]
12. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
13. Differences in practice patterns and costs between small cell and non-small cell lung cancer patients in Japan.
Kuwabara K; Matsuda S; Fushimi K; Anan M; Ishikawa KB; Horiguchi H; Hayashida K; Fujimori K
Tohoku J Exp Med; 2009 Jan; 217(1):29-35. PubMed ID: 19155605
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
17. Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?
Lim C; Sung M; Shepherd FA; Nouriany N; Sawczak M; Paul T; Perera-Low N; Foster A; Zawisza D; Feld R; Liu G; Leighl NB
J Thorac Oncol; 2016 Jan; 11(1):79-84. PubMed ID: 26762742
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy.
Harewood GC; Wiersema MJ; Edell ES; Liebow M
Mayo Clin Proc; 2002 Feb; 77(2):155-64. PubMed ID: 11838649
[TBL] [Abstract][Full Text] [Related]
19. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
20. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.
Bremner KE; Krahn MD; Warren JL; Hoch JS; Barrett MJ; Liu N; Barbera L; Yabroff KR
Palliat Med; 2015 Dec; 29(10):918-28. PubMed ID: 26330452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
